Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVISE: FOLFOXIRI vs XELOX in ctDNA+ Stage III Colon Cancer
NCT06242418Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan in colon cancer (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Change in value of ctDNA concentration at 6 months. Started Mar 2024; status: recruiting.
02
Drugs
irinotecan
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT06242418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06242418.